Contact Information
37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG
We Are Available 24/ 7. Call Now.
Biogen: BIIB080 Phase 1b Study Shows Reduction Of Tau PET Across Brain Regions
(RTTNews) – Biogen Inc. (BIIB) reported Phase 1b clinical data showing that the investigational antisense oligonucleotide therapy, BIIB080, reduced soluble tau protein in cerebrospinal fluid